Summary:
- The PARP inhibitors market is expected to experience significant growth by 2034, driven by the wider opportunity in multiple indications with HRR and BRCA gene mutations.
- The increasing cost of therapy for leading PARP inhibitors in the US is a key factor contributing to the market growth.
- The article highlights the potential of PARP inhibitors in addressing various cancer types and the ongoing research and development efforts in this field.